trending Market Intelligence /marketintelligence/en/news-insights/trending/kyuoQkCBRgyFJ07CkzG48A2 content esgSubNav
In This List

Acorda Therapeutics to reduce staff by 25% to focus on Parkinson's therapy

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Acorda Therapeutics to reduce staff by 25% to focus on Parkinson's therapy

Acorda Therapeutics Inc. is reducing its workforce by 25% in a restructuring to focus its resources on the launch of its Parkinson's disease treatment Inbrija.

The Ardsley, N.Y.-based drugmaker said it expects the workforce reduction to be completed in the first quarter of 2020.

Inbrija is a formulation of levodopa, one of the main drugs used to treat certain symptoms of Parkinson's disease. The therapy is used for patients experiencing so-called off periods when the effects of an existing medication start to wear off in between doses or the symptoms of Parkinson's reemerge.

The drug is approved by the U.S. Food and Drug Administration and the European Commission.